Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial-Reference-Cited by-同舟云学术

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial

Published:2021-11-25 Issue:3 Volume:29 Page:790-801
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Vermersch Patrick¹,Oreja‐Guevara Celia²,Siva Aksel³,Van Wijmeersch Bart⁴,Wiendl Heinz⁵,Wuerfel Jens⁶,Buffels Regine⁷,Kadner Karen⁷,Kuenzel Thomas⁷,Comi Giancarlo⁸,

Affiliation:

1. Univ. Lille, Inserm U1172 LilNCog CHU Lille FHU Precise Lille France

2. Hospital Clínico San Carlos Madrid Spain

3. Istanbul University Cerrahpasa School of Medicine Istanbul Turkey

4. University MS Centre, Pelt Hasselt University Hasselt Belgium

5. Department of Neurology with Institute of Translational Neurology University of Münster Münster Germany

6. Medical Image Analysis Center (MIAC AG) Department of Biomedical Engineering University of Basel Basel Switzerland

7. F. Hoffmann‐La Roche Ltd Basel Switzerland

8. Vita‐Salute San Raffaele University Milan Casa di Cura del Policlinico Milan Italy

Publisher

Wiley

Subject